comparemela.com

Latest Breaking News On - Hepion pharmaceuticals inc - Page 1 : comparemela.com

Dow Jumps Over 100 Points; Chicago Fed National Activity Rises In March - Moolec Science (NASDAQ:MLEC), Hepion Pharmaceuticals (NASDAQ:HEPA)

S&P 500 Rises Over 1%; Zions Bancorp Shares Gain After Q1 Earnings - Moolec Science (NASDAQ:MLEC), Hepion Pharmaceuticals (NASDAQ:HEPA)

Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday? - Hepion Pharmaceuticals (NASDAQ:HEPA)

Updates on Hepion Pharmaceuticals' ASCEND-NASH Trial, now in wind-down phase. Explore insights into Phase 2b study progression and strategic alternatives.

Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?

Friday, Hepion Pharmaceuticals Inc. HEPA said it has begun winding down activities in its ASCEND-NASH Trial while continuing to explore strategic…

Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?

Friday, Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) said it has begun winding down activities in its ASCEND-NASH Trial while continuing to explore strategic alternatives, as announced in December 2023. ASCEND-NASH is a Phase 2b, randomized, multicenter, double-blinded study with the first patient screened in August 2022 to evaluate the safety and efficacy of rencofilstat dosed for 12 months, with a target enrollment of 336 subjects. Enrollment was paused in April 2023, with 151 subjects randomized

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.